Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Vale SA — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B), while Vale SA trades at $13.6 (market cap $57.32B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) and Vale SA are close in size by market cap, and Vale SA pays the higher dividend (8.87%). Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and Vale SA for 109 Days on average.
| TAK | VALE | |
|---|---|---|
Market Cap | $58.74B | $57.32B |
Volume | 3,110,994 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $19.05 | $17.82 |
52-Week Low | $13.23 | $10.75 |
Typical Hold Time | 0 Days | 109 Days |
Enterprise Value | $86.65B | $73.56B |
Dividend Yield | 3.33% | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VALE trades at $13.61, down 3.34% amid broader market weakness in mining stocks. The stock shows bearish technical signals with recent earnings misses and declining profit margins (5.11% net margin in 2025). Revenue has stabilized around $38-41B, but iron ore pricing pressure and rising costs challenge near-term profitability. Analyst consensus remains mixed with 32% buy ratings despite a $16.21 price target suggesting 19% upside potential.
The investment case balances Vale's position as a low-cost iron ore producer against cyclical commodity exposure and Brazilian regulatory risks. Base metals growth provides diversification, but margin compression and debt increases warrant caution. Current valuation at 27x P/E appears stretched given earnings volatility, making risk-reward balanced for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
